Levopropoxyphene

Summary

Levopropoxyphene (CHEMBL1738990) is an approved small-molecule antitussive.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 339.5 Da · C22H29NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1738990
Name	Levopropoxyphene
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	200742
ChEBI	CHEBI:51174
Molecular formula	C22H29NO2
Molecular weight	339.5
InChIKey	XLMALTXPSGQGBX-PGRDOPGGSA-N

SMILES: CCC(=O)O[C@@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@@H](C)CN(C)C

IUPAC name: [(2R,3S)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate

Pharmacological roles (ChEBI): antitussive.

Also known as: (-)-propoxyphene, L-propoxyphene, Levopropoxifeno, Levopropoxyphene, Propoxyphene, (-)-, Propoxyphene, l-, LEVOPROPOXYPHENE, levopropoxyphene, (+)-Alpha-propoxyphene

Parent form; salt/anhydrous children: CHEMBL1593906

Patent coverage: 182 distinct patent families (654 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Voltage-gated inwardly rectifying potassium channel KCNH2, Mas-related G-protein coupled receptor member X2.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
KCNH2	5.56	IC50	2754	nM	CHEMBL_ACT_5218998

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).